HUP0103003A2 - PEG/karbamát oxidáz konjugátumok és alkalmazásuk - Google Patents

PEG/karbamát oxidáz konjugátumok és alkalmazásuk

Info

Publication number
HUP0103003A2
HUP0103003A2 HU0103003A HUP0103003A HUP0103003A2 HU P0103003 A2 HUP0103003 A2 HU P0103003A2 HU 0103003 A HU0103003 A HU 0103003A HU P0103003 A HUP0103003 A HU P0103003A HU P0103003 A2 HUP0103003 A2 HU P0103003A2
Authority
HU
Hungary
Prior art keywords
uricase
peg
conjugates
poly
subject
Prior art date
Application number
HU0103003A
Other languages
English (en)
Inventor
Michael S. Hershfield
Susan J. Kelly
Mark G. P. Saifer
Merry R. Sherman
L. David Williams
Original Assignee
Duke University
Mountain View Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University, Mountain View Pharmaceuticals, Inc. filed Critical Duke University
Publication of HUP0103003A2 publication Critical patent/HUP0103003A2/hu
Publication of HUP0103003A3 publication Critical patent/HUP0103003A3/hu
Publication of HU226294B1 publication Critical patent/HU226294B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A találmány tárgyát poli(etilén-glikolok) és poli(etilén-oxidok)karbamát oxidáz (urikáz) enzimmel alkotott konjugátumai képezik,amelyek a nem konjugált urikáz urikolitikus aktivitásának legalább kb.75%-át megtartják, lényegében nem immunogének, és alegységekből állóurikázt, valamint ahhoz kovalens kötéssel kapcsolt, alegységenkéntátlagosan 2-10 szál, kb. 5 kD és 100 kD közötti molekulatömegű PEG-ettartalmaznak. Szintén a találmány tárgyához tartoznak a találmányszerinti PEG-urikáz konjugátumokat tartalmazó gyógyászatikészítmények; eljárások urikáz tetramer alakjának izolálására;valamint az izolálási eljárással kapott tetramer urikázok. Ó
HU0103003A 1998-08-06 1999-08-02 Peg-urate oxidase conjugates and use thereof HU226294B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13039298A 1998-08-06 1998-08-06
PCT/US1999/017514 WO2000007629A2 (en) 1998-08-06 1999-08-02 Peg-urate oxidase conjugates and use thereof

Publications (3)

Publication Number Publication Date
HUP0103003A2 true HUP0103003A2 (hu) 2001-11-28
HUP0103003A3 HUP0103003A3 (en) 2006-04-28
HU226294B1 HU226294B1 (en) 2008-08-28

Family

ID=22444494

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0103003A HU226294B1 (en) 1998-08-06 1999-08-02 Peg-urate oxidase conjugates and use thereof
HU0800112A HU228916B1 (en) 1998-08-06 1999-08-02 Polyethylen-glycol/carbamate oxydase conjugates and pharmaceutical compositions containing thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
HU0800112A HU228916B1 (en) 1998-08-06 1999-08-02 Polyethylen-glycol/carbamate oxydase conjugates and pharmaceutical compositions containing thereof

Country Status (13)

Country Link
EP (1) EP1100542B1 (hu)
JP (3) JP5183836B2 (hu)
KR (2) KR100488848B1 (hu)
AU (1) AU770014B2 (hu)
BR (2) BRPI9912974B8 (hu)
CZ (1) CZ303751B6 (hu)
HU (2) HU226294B1 (hu)
IL (3) IL141220A0 (hu)
NZ (1) NZ509595A (hu)
PL (2) PL202799B1 (hu)
RU (3) RU2246318C2 (hu)
TW (1) TW570981B (hu)
WO (1) WO2000007629A2 (hu)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
CA2338665C (en) 1998-08-06 2011-01-18 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
PT1100880E (pt) 1998-08-06 2011-01-13 Univ Duke Urato-oxidase
JP5183836B2 (ja) * 1998-08-06 2013-04-17 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド Ｐｅｇ−尿酸酸化酵素結合体およびその使用
AU2006203252B8 (en) * 2000-02-10 2009-06-18 Duke University Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
KR100777195B1 (ko) 2000-04-03 2007-11-19 산텐 세이야꾸 가부시키가이샤 송달성 물질 및 이를 이용한 약물 송달 시스템
EP1317258B1 (en) 2000-06-28 2009-02-11 Merck & Co., Inc. Use of allopurinol for the treatment of hypertension
US7229810B2 (en) 2001-06-28 2007-06-12 Mountain View Pharmaceuticals, Inc. Polymer conjugates of proteinases
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
ES2395413T3 (es) 2003-05-12 2013-02-12 Affymax, Inc. Péptidos que se unen al receptor de eritropoyetina
MXPA05012314A (es) 2003-05-12 2006-04-18 Affymax Inc Radical separador para peptido modificado con polietilenglicol.
JP2008505119A (ja) * 2004-06-30 2008-02-21 ネクター セラピューティクス アラバマ，コーポレイション 高分子−第ｉｘ因子部分の抱合体
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
EP1871877A2 (en) 2005-04-11 2008-01-02 Savient Pharmaceuticals, Inc. A variant form of urate oxidase and use thereof
ES2856881T3 (es) 2005-04-11 2021-09-28 Horizon Pharma Rheumatology Llc Formas variantes de urato oxidasa y su uso
WO2006121995A2 (en) 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
ES2532804T3 (es) * 2006-04-12 2015-03-31 Crealta Pharmaceuticals Llc Purificación de proteínas con tensioactivo catiónico
JP4890132B2 (ja) * 2006-07-20 2012-03-07 東洋紡績株式会社 ウリカーゼの比活性を向上させる方法、および比活性の向上した改変型ウリカーゼ
AU2010265964B2 (en) 2009-06-25 2014-09-18 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
NZ623294A (en) * 2010-03-02 2015-10-30 Protalix Ltd Stabilized alpha-galactosidase and uses thereof
KR101797936B1 (ko) 2010-09-10 2017-11-15 다케다 파마슈티칼스 유에스에이, 인코포레이티드 테오필린과 페북소스타트의 병용 치료 방법
CN102634492B (zh) 2011-02-14 2015-06-10 重庆富进生物医药有限公司 聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用
US9744175B2 (en) 2012-04-06 2017-08-29 Indus Pharmaceuticals, Inc. Compositions of combinations of non-covalent DNA binding agents and anti-cancer and/or anti-inflammatory agents and their use in disease treatment
EP3294322A4 (en) * 2015-05-15 2018-12-12 Medimmune, LLC Improved uricase sequences and methods of treatment
CN105412942B (zh) * 2015-12-23 2019-02-26 沈阳三生制药有限责任公司 聚乙二醇化的重组产朊假丝酵母尿酸氧化酶冻干注射剂
CN112980808A (zh) * 2019-12-12 2021-06-18 深圳迈瑞生物医疗电子股份有限公司 尿酸酶、及其制备方法和用途
WO2022097141A1 (en) 2020-11-03 2022-05-12 Protalix Ltd. Modified uricase and uses thereof
JPWO2022172343A1 (hu) 2021-02-10 2022-08-18
CN114181917B (zh) * 2022-02-14 2022-06-03 潍坊华卓生物科技有限公司 一种改造尿酸酶、基因序列、制备方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55135590A (en) * 1979-04-05 1980-10-22 Mihama Hisaharu Modified asparaginase and uricase and their preparation
JPS57192435A (en) * 1981-05-20 1982-11-26 Toyobo Co Ltd Modified polypeptide
JPS6255079A (ja) * 1986-04-23 1987-03-10 Mihama Hisaharu 修飾ウリカ−ゼ
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
PT1100880E (pt) * 1998-08-06 2011-01-13 Univ Duke Urato-oxidase
JP5183836B2 (ja) * 1998-08-06 2013-04-17 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド Ｐｅｇ−尿酸酸化酵素結合体およびその使用

Also Published As

Publication number Publication date
HU228916B1 (en) 2013-06-28
TW570981B (en) 2004-01-11
EP1100542A2 (en) 2001-05-23
BR9917760B1 (pt) 2014-11-25
EP1100542B1 (en) 2005-06-22
KR100488848B1 (ko) 2005-05-11
WO2000007629A3 (en) 2000-06-08
KR20010072287A (ko) 2001-07-31
JP2013039139A (ja) 2013-02-28
JP5291235B2 (ja) 2013-09-18
IL183948A0 (en) 2007-10-31
IL141220A0 (en) 2002-03-10
AU5251599A (en) 2000-02-28
RU2278680C2 (ru) 2006-06-27
BRPI9917760B8 (pt) 2021-05-25
BRPI9912974B8 (pt) 2021-05-25
IL183948A (en) 2010-11-30
NZ509595A (en) 2004-02-27
JP5290901B2 (ja) 2013-09-18
PL346224A1 (en) 2002-01-28
PL383331A1 (hu) 2002-01-28
HU226294B1 (en) 2008-08-28
CZ303751B6 (cs) 2013-04-24
RU2006107111A (ru) 2007-09-20
WO2000007629A2 (en) 2000-02-17
JP5183836B2 (ja) 2013-04-17
IL141220A (en) 2007-09-20
RU2246318C2 (ru) 2005-02-20
AU770014B2 (en) 2004-02-12
CZ2001317A3 (cs) 2001-07-11
BRPI9912974B1 (pt) 2015-08-25
RU2004104953A (ru) 2005-07-27
KR20040088585A (ko) 2004-10-16
PL220873B1 (pl) 2016-01-29
PL202799B1 (pl) 2009-07-31
JP2002522399A (ja) 2002-07-23
KR100614212B1 (ko) 2006-08-21
HUP0103003A3 (en) 2006-04-28
RU2349341C2 (ru) 2009-03-20
BR9912974A (pt) 2001-05-08
JP2009254376A (ja) 2009-11-05

Similar Documents

Publication Publication Date Title
HUP0103003A2 (hu) PEG/karbamát oxidáz konjugátumok és alkalmazásuk
CY1119848T1 (el) Απομονωμενη τετραμερικη ουρικαση
Schiavon et al. Therapeutic proteins: a comparison of chemical and biological properties of uricase conjugated to linear or branched poly (ethylene glycol) and poly (N-acryloylmorpholine)
AU743108B2 (en) Non-antigenic branched polymer conjugates
RU2002120486A (ru) Свободная от агрегатов уратоксидаза для приготовления неиммуногенных полимерных конъюгатов
JP2003521937A5 (hu)
WO2002026265A3 (en) Pegylated interleukin-10
RU2009104003A (ru) Выделенная уратоксидаза, очищенная химерная уратоксидаза и ее конъюгаты, очищенные фрагменты уратоксидазы, конъюгаты очищенной уратоксидазы (варианты), фармацевтическая композиция на основе конъюгата очищенной уратоксидазы, способ очистки уратоксидазы и выделенная уратоксидаза, полученная этим способом
ATE497781T1 (de) Impfstoffe auf mannoproteinfreier beta-glucan- basis
WO2001045796A3 (en) Method for the preparation of 1-benzotriazolyl carbonate esters of poly(ethylene glycol)
WO2005028539A3 (en) Multi-arm polymer prodrugs
HUP0101749A2 (hu) Készítmények PEG-interferon-alfa-konjugátumok védelmére és eljárás ilyen készítmények előállítására
BR0209699A (pt) Composições de conjugado de lipìdeo-polìmero
UA100967C2 (ru) Конъюгаты нейбластина с полимерами и способы их применения
WO2005094424A3 (en) Use of the pro-peptide domain of lysyl oxidase as a therapeutic agent
CY1114005T1 (el) Συζευγματα peg-ουρικης οξειδασης και χρηση αυτων

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees